Short answer
ClearPoint Neuro, Inc. (CLPT) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Q3 fiscal 2026 results announced for the quarter ended September 30, 2026.
ClearPoint Neuro, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 results announced for the quarter ended September 30, 2026
- Full financial details and management commentary contained in Exhibit 99.1
- Results release provides investors the company’s latest quarterly operating and financial update
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation posted October 28, 2026, signaling refreshed messaging for analysts and investors
- Presentation available as Exhibit 99.2 and intended for use in future investor communications
- Investor relevance depends on updated operating, pipeline, or financial information contained in the presentation
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $12.1M, up 36% year over year, with growth outpacing operating-expense growth of 23%
- Neurosurgery navigation and therapy revenue $5.4M, up 59%, primarily reflecting IRRAflow sales after the IRRAS acquisition
- Gross margin fell to 58% from 63%, pressured by Advanced Laboratories overhead and acquired-intangible amortization
- Net loss widened to $7.5M from $5.9M, while interest expense increased to $1.4M from $0.9M
- 2026 revenue guidance set at $48.0M to $50.0M, supported by $46.2M cash after $22.0M ATM proceeds and $20.1M operating cash use
Item EX-99.2 · Exhibit EX-99.2
- Investor presentation outlines 2026 strategy, expanding from four to five growth pillars with commercial cell and gene therapy delivery
- 2026 revenue guidance of $48.0-$50.0 million, versus $37.0 million in 2025
- Cash and equivalents $46.2 million, with 61% gross margin reported for the quarter ended September 30, 2026
- Platform scale: 175+ active global centers, 60+ pharma partners, 25+ active clinical trials, and 10+ programs under FDA expedited review
- Management targets $200 million annual revenue from existing markets and an additional $300 million from 20,000 annual cell and gene therapy procedures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ClearPoint Neuro, Inc. 8-K filings
Get the next CLPT 8-K as it lands
Follow CLPT for push alerts, or ask the research agent what this filing means.